EN | UA
EN | UA

Help Support

Back

OnabotulinumtoxinA combats not only chronic migraine but also associated comorbidities

OnabotulinumtoxinA combats not only chronic migraine but also associated comorbidities OnabotulinumtoxinA combats not only chronic migraine but also associated comorbidities
OnabotulinumtoxinA combats not only chronic migraine but also associated comorbidities OnabotulinumtoxinA combats not only chronic migraine but also associated comorbidities

What's new?

OnabotulinumtoxinA treatment helps to improve sleep quality, reduce fatigue symptoms with promising effects beyond those of headache frequency reduction, especially in chronic migraine patients with psychiatric comorbidities.

OnabotulinumtoxinA not only reduces anxiety, fatigue and depression but also reduces headache frequency and improve symptoms of poor sleep quality, as per the information gained by a recent open-label, prospective, multicentre analysis of the Journal of Neurology, Neurosurgery, and Psychiatry.

A total of nine treatments were given to patients with chronic migraine (CM) under the Chronic Migraine OnabotulinumtoxinA Prolonged Efficacy open-Label (COMPEL) study. Efficacy of OnabotulinumtoxinA on depression and anxiety assessed by applying the Generalised Anxiety Disorder (GAD-7) and The Patient Health Questionnaire (PHQ-9) scales, respectively and clinical improvement by the percentage of participants enduring a ≥1 severity category decrease in GAD-7 and PHQ-9. The Fatigue Severity Scale and the Pittsburgh Sleep Quality Index were used to measure the association of onabotulinumtoxinA with fatigue and sleep quality.

A sustained decline in PHQ-9, GAD-7 scores and headache days were noticed with OnabotulinumtoxinA treatment over 108 weeks. GAD-7 and PHQ-9 scores were considerably decreased at all time points among participants with clinically notable signs of anxiety and/or depression at baseline. Fatigue and sleep quality were also improved, although, limited is known regarding clinically important changes in these measures. No adverse effects were noticed during the analysis. These findings demonstrated Onabotulinumtoxin A as an important treatment regimen for chronic migraine. 

Source:

The Journal of Neurology, Neurosurgery, and Psychiatry

Article:

Effects of onabotulinumtoxin A treatment for chronic migraine on common comorbidities including depression and anxiety

Authors:

Andrew M Blumenfeld et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: